mRNA Therapeutics

Biopharmaceutical excipients are the inactive substances added to biologic drug products to protect large, structurally fragile biomolecules, such as monoclonal...

Messenger RNA (mRNA) is intrinsically unstable due to spontaneous 2'-hydroxyl-mediated phosphodiester hydrolysis, with degradation rates accelerating at pH below 5.0...

This year, the 15th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology took place in Prague, Czech Republic. We show...

Abstract Ionizable aminolipids enable lipid nanoparticles (LNPs) to encapsulate nucleic acids at neutral pH and to release their cargo upon...

Abstract Since the first market authorization of RNA therapies, just eight years ago, the field has witnessed an extraordinary expansion,...

Abstract KRAS G12S mutations in non-small cell lung cancer (NSCLC) remain refractory to current targeted therapies, with few clinical options and...

Highlights PLGA/PBAE coordinates endosomal escape and timely mRNA release in APCs PLGA/PBAE enhances mRNA transfection in APCs and promotes immune...

Abstract Background: An efficient formulation of lipid nanoparticles (LNPs) is often considered crucial in the successful development of nucleic acid...

Abstract Small interfering RNA (siRNA)-loaded lipid nanoparticles (LNPs) are a promising modality for gene silencing therapies. Pulmonary delivery offers an...

Abstract During the pandemic, lipid nanoparticles (LNPs) became widely established as RNA nanocarriers, and hold the promise of future targeting...